AstraZeneca PLC · LSE:AZN
AstraZeneca — Investor Presentation (1999)
22 slides from AstraZeneca's investor presentation, 1999
Slide 1: AstraZeneca Respiratory
AstraZeneca Respiratory Colin Reddrop Vice President & Head of Respiratory TA Goal To be the company of first choice for our customers by offering a strong portfolio of products for the treatment of h Asthma h Chronic Obstructive Pulmonary Disease
Slide 2: Overview of global market
Overview of global market Respiratory systems - sales split by disease segment $18.4 billion - 2Q MAT 1999 (source IMS) 27% 37% Asthma COPD Rhinitis/ Sinusitis/ Nasal Polyps Others* 11% * Approximately 60% of others appear to be accounted for by cough & cold and allergy diagnoses 25% Overview of glo
Slide 3: AstraZeneca in asthma
AstraZeneca in asthma The most complete range of products and inhalation devices for the treatment of asthma - mild, moderate & severe Asthma product portfolio strength Symbicort Bambec Bricanyl
Slide 4: Inhalation devices strength
Inhalation devices strength Turbuhaler® h Simple h Effective h Easy to teach h Easy to learn
Slide 5: Pulmicort - inhaled steroid
Pulmicort® - inhaled steroid Turbuhaler®, pMDI, Respules® h Once daily claim – intra-cellular binding leading to longer-lasting local effects Pulmicort® Turbuhaler® START - study of early intervention in asthma h A global long-term prospective study of Pulmicort® Turbuhaler® once daily in asthma h T
Slide 6: Pulmicort Turbuhaler US situation; Oxis rapid onset
Pulmicort® Turbuhaler® US situation h First generation of Turbuhaler® launched h Strong acceptance by doctors, patients – market shares ca. 20% where supply = demand h Current supply limitations being addressed, together with FDA where relevant – building additional capacity for current process – ap
Slide 7: Oxis Turbuhaler - long duration of action
Oxis® Turbuhaler® - long duration of action FEV1 (L) 2.8 Placebo 2.6 4.5 µg formoterol Turbuhaler® 2.4 9 µg formoterol Turbuhaler® 2.2 18 µg formoterol Turbuhaler® 50 µg salmeterol Diskhaler 0 2 4 6 8 10 12 Time Palmqvist M et al, 1997 (hours) development Slide not published
Slide 8: Oxis development; FACET severe exacerbation rate
development In addition, a unique as needed (p.r.n.) claim is currently under regulatory review h Oxis® Turbuhaler® will be the only long-acting bronchodilator recommended for both – acute relief of bronchoconstriction – regular twice-daily use as a long-acting bronchodilator h A pMDI delivery syste
Slide 9: FACET change in morning PEF; Symbicort Turbuhaler
FACET-change in morning PEF from baseline 40 Change in PEF (litres/minute) 30 20 10 0 -10 -20 -30 Pulmicort® 200 Pulmicort® 200+Oxis® Pulmicort® 800 Pulmicort® 800+Oxis® -40 0 1 2 3 6 9 12 Time (months) Symbicort® Turbuhaler® budesonide plus formoterol hImproves asthma symptoms hImproves lung functi
Slide 10: Symbicort Turbuhaler Phase III results
Symbicort® Turbuhaler® Phase III results 400 390 (L/min) 380 370 Change from run-in (L/min) 360 350 -10 0 10 20 30 40 50 60 70 80 90 Symbicort® Pulmicort®+Oxis® Pulmicort® 50 40 30 20 10 0 -10 -10 0 10 20 30 40 50 60 70 80 90 Days since randomisation Symbicort® Development status h Unique properties
Slide 11: Device developments
Device developments Dry Powder Inhalers (DPI’s) h The new generation “M3” Turbuhaler® is in development for NDA – Symbicort® 4Q 1999 – Pulmicort® 1H 2001 – Viozan™ 2H 2001 – future inhaled NCE’s h A proprietary non-reservoir DPI is also in development Device developments Pressurised Metered Dose Inh
Slide 12: Accolate oral leukotriene antagonist
Accolate® oral leukotriene antagonist Sales to date have been affected by h Twice daily vs once daily regimen h No paediatric claims or dosage forms h Food interactions in labelling h Initial safety issues, including CSS Accolate® development However, we are now implementing – paediatric claims – ap
Slide 13: LTRAs - exacerbation rates
LTRAs - exacerbation rates 12 h No direct comparison Failure or rescue % 10 8 to date 6 h Other parameters 4 similar (FEV1, PEFR, 2 ß-agonist use) 0 Accolate montelukast h Data drawn from study drug placebo pack inserts Accolate® development h Paediatric claim – approved in USA 3Q 99 – completing de
Slide 14: AstraZeneca in Asthma and COPD
AstraZeneca in Asthma The most complete range of products and inhalation devices for the treatment of asthma - mild, moderate & severe AstraZeneca in COPD Developing a new wave of products h Offering the patient and prescriber a true portfolio of treatment options for the spectrum of COPD symptoms
Slide 15: Developing a product portfolio in COPD
Developing a product portfolio in COPD Asthma COPD Developing a product portfolio in COPD Asthma Bronchitis COPD
Slide 16: COPD - sales by product group
Developing a product portfolio in COPD Asthma Bronchitis COPD Emphysema Overview of global market COPD - sales by product group 2Q MAT 1999 3%2% 1% 10% 30% Beta-agonists Inhaled corticosteroids Anticholinergics Xanthines 25% Leukotriene antagonists Antiallergics Others 29%
Slide 17: AstraZeneca in COPD; Viozan
AstraZeneca in COPD h A new wave of documented treatments for the full range of COPD severity & symptoms – Pulmicort® – Oxis® – Symbicort® and introducing the newest treatment option h Viozan™ - the drug of choice for the treatment of COPD symptoms Viozan™ Dual dopamine & beta agonist Inflammatory c
Slide 18: Viozan - drug of choice for COPD symptoms
Viozan™ The drug of choice for the treatment of COPD symptoms Study 1 Slide not published Viozan™ The drug of choice for the treatment of COPD symptoms Study 2 Slide not published
Slide 19: Slide not published
Viozan™ The drug of choice for the treatment of COPD symptoms Study 2 Slide not published Viozan™ The drug of choice for the treatment of COPD symptoms Study 2 Slide not published
Slide 20: Viozan development status
Viozan™ development status h Phase III programme has commenced h NDA scheduled for 2H 2001 Viozan™ - the drug of choice for the treatment of COPD symptoms AstraZeneca in COPD Oxis® asthma-like symptoms Viozan™ Symbicort® sputum exacerbations Asthma Bronchitis Viozan™ COPD cough Pulmicort® Emphysema
Slide 21: Key brand filing dates
Key brand filing dates Viozan™ pMDI Pulmicort® NDA (EU+US) Symbicort® ZD0892 COPD M3(US) pMDI (EU) global NDA Turbuhaler® (EU) Accolate® Paed EU Viozan™ (Jap) 99 00 01 02 03 04 05 06 07 08 09 Oxis® prn in Symbicort® Viozan™ AR-C89855 asthma (EU) Turbuhaler® Turbuhaler global NDA NDA ® (US) asthma(EU
Slide 22: Slide 22